Coherus BioSciences: Pure Play In The Emerging Biosimilar In

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Coherus BioSciences: Pure Play In The Emerging Biosimilar In

An SI Board Since January 2015

Posts	SubjectMarks	Bans	Symbol
9	10	0	CHRS

Emcee: Arthur Radley	Type: Moderated

Introduction Market Data Compact

The following company is how I'm playing this evolving issue for lowering the price for drugs. The company is Coherus Biosciences(CHRS) domiciled in Redwood City, California. The company issued their IPO back in November, 2014, at the price of $13.50 per share. Coherus is a pure play in the emerging biosimilar market for drugs. With Novartis getting FDA approval this week, for the first biosimilar product in the US, this in my opinion opens the door for other companies who have strong analytic skills and management. Coherus has three drugs in development with one in final Phase III testing that should allow them to file their BLA later this year. They also have partnership deals with Baxter and Daiichi-Sanyo. Since going public in November the stock is up more than 65%, but if they get approval of their lead candidate(Humira) the price of the stock at this level would be a bargain.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
9	JP Morgan increased target price to $35 with an overweight rating. (Today)	Arthur Radley	-	2/17/2015
8	Was a good presentation! Yesterday and today, I hope is merely a case of profit	Arthur Radley	-	2/11/2015
7	CHRS’ Leerink webcast has a good discussion of the pros and cons of the 351(k) p	DewDiligence_on_SI	-	2/11/2015
6	Some investors think the PFE-HSP deal is mostly about FoBs, but I would say it’s	DewDiligence_on_SI	-	2/7/2015
5	Appears the PFE and Hospira deal caught investor's eye-------at least for ye	Arthur Radley	-	2/7/2015
4	On reduced volume the stock has pulled back about 20% from recent high, so I dou	Arthur Radley	-	1/16/2015
3	Stock hits new high today ($23.76), being up about 5%. Wonder what it would do i	Arthur Radley	-	1/14/2015
2	That number of Phase III programs does seem like a tall mountain to climb, but r	Arthur Radley	-	1/12/2015
1	CHRS says it can start one phase-3 FoB trial every 2 years. (Source: JPM webcast	DewDiligence_on_SI	-	1/12/2015

Go to reply# or date (mm/dd/yy):